Silicone Polymer Compound for Transdermal Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional transdermal drug delivery systems face limitations such as drug stability, hepatic first-pass metabolism, low water solubility, and limited absorption due to enzymatic degradation and permeability issues, necessitating the development of a new polymer with improved biocompatibility and controlled release properties.
Innovation Solution
A silicone polymer compound represented by Chemical Formula 1, synthesized through ring-opening polymerization of specific monomers with initiators like citric acid, trifluoroacetic acid, or hydrochloric acid, offering controlled molecular weight, viscosity, and encapsulation efficiency for transdermal delivery of active substances, including anticancer agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chitosan is used as a gelling agent to induce drug absorption through cell membrane depolarization, then absorption of active ingredients is improved, but the encapsulated drug is degraded by proteolytic enzymes at physiological pH
Solution Approach 1:
The patent modifies the chemical structure of chitosan by controlling the degree of deacetylation (DA value) to be within 60-90%, and adjusts the molecular weight and acetylation degree as key parameters. This optimization allows the polymer to maintain cell membrane permeability enhancement while reducing susceptibility to proteolytic degradation, thus resolving the contradiction between absorption promotion and drug stability.
Solution Approach 2:
The patent creates a composite gel formulation combining chitosan with additional polymers or excipients that provide proteolytic enzyme resistance. This composite approach allows the system to benefit from chitosan's membrane permeability effects while the additional components protect against enzymatic degradation of the encapsulated drug.
2Reliability
If hyaluronic acid-based nanoliposomes are used for drug encapsulation, then particle stability and skin permeability are improved, but drug delivery to the dermal layer is limited due to retention within the epidermal layer
Solution Approach 1:
The patent modifies the nanoliposome structure by incorporating hydrophilic polymers with specific molecular weights and charges to create local quality differences within the liposome membrane. This allows enhanced interaction with dermal tissues while maintaining epidermal penetration, thereby improving drug delivery to the target layer without compromising particle stability.
Solution Approach 2:
The patent optimizes parameters including the ratio of hydrophilic polymer to lipid in the nanoliposome formulation, the molecular weight of the hydrophilic polymer, and the charge density to control the depth of drug penetration. These parameter adjustments enable the system to overcome the retention barrier in the epidermal layer while maintaining stability.
3Object-affected harmful factors
If poly(dimethylsiloxane) is used in transdermal patch formulations, then inertness and non-toxicity are improved, but drug release is limited by strong binding to encapsulated drug
Solution Approach 1:
The patent creates a composite system combining poly(dimethylsiloxane) with hydrophilic polymers or surfactants that modify the binding characteristics. This composite formulation maintains the inertness and non-toxicity of poly(dimethylsiloxane) while the additional components enhance drug release by reducing strong binding interactions.
Solution Approach 2:
The patent adjusts parameters such as the molecular weight of poly(dimethylsiloxane), the concentration of hydrophilic additives, and the ratio of hydrophilic to hydrophobic components to optimize the balance between maintaining polymer stability and enhancing drug release rates.
4Ease of manufacture
If gel formulations are used for transdermal delivery, then ease of formulation is improved, but the encapsulated drug must have low molecular weight and sufficient hydrophobicity which limits the range of effective drugs
Solution Approach 1:
The patent develops a composite gel system combining chitosan with hydrophilic polymers and surfactants that expand the range of compatible drugs. This composite formulation maintains the simplicity of gel-based delivery while the multi-component system can accommodate both hydrophilic and hydrophobic drugs through appropriate interaction mechanisms.
Solution Approach 2:
The patent optimizes parameters including the degree of deacetylation of chitosan, the molecular weight distribution, the hydrophilic-to-hydrophobic ratio, and the concentration of additives to create a gel formulation that can effectively deliver a broader spectrum of drugs with varying properties while maintaining formulation simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silicone polymer compound demonstrates high biocompatibility, enhanced absorption and penetration rates, and effective cancer treatment by maintaining drug release and reducing tumor size/volume without toxicity, improving upon existing polymer limitations.
Implementation Method 1
the TDDS may be used to deliver various hydrophilic and hydrophobic drugs... the gel formulation allows the drug to be absorbed into the skin using passive diffusion
Data Source
AI summary
The present invention relates to a silicone polymer compound, a method for preparing same, a composition for transdermal delivery comprising same, and an anti-cancer composition comprising same, wherein a cyclic silane is used as a monomer, and the molecular weight, viscosity, contact angle, moisture content, drug encapsulation ratio, and release behavior of a synthesized silicone polymer compound can be controlled by controlling polymerization conditions such as the type of initiator, ratio of initiator to monomer, and polymerization temperature, and the synthesized silicone polymer compound can thus be used as a transdermal delivery system loaded with a drug and various active substances. In addition, by encapsulating an anticancer agent in the silicone polymer compound of the present invention, the effect of the anticancer agent can be enhanced, and the silicone polymer compound can thus also be utilized for an anticancer use.